Fieldview Capital Management LLC Purchases New Stake in Jazz Pharmaceuticals PLC $JAZZ

Fieldview Capital Management LLC purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,967 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,864,000.

A number of other institutional investors have also recently modified their holdings of the business. Cardinal Capital Management boosted its stake in shares of Jazz Pharmaceuticals by 0.5% in the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 9.0% in the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 81 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 81 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after purchasing an additional 83 shares during the last quarter. Finally, Fairbanks Capital Management Inc. raised its holdings in Jazz Pharmaceuticals by 0.4% during the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after purchasing an additional 94 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on JAZZ. Morgan Stanley reaffirmed an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Piper Sandler lifted their price objective on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, May 22nd. Barclays lifted their price objective on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Truist Financial set a $256.00 price objective on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Finally, Royal Bank Of Canada lifted their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $246.06.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Negative Sentiment: Jazz Pharmaceuticals said the Phase 3 LAGOON trial for Zepzelca did not meet its primary endpoint of overall survival in second-line small cell lung cancer. Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
• Negative Sentiment: Reuters reported the trial failure could put Zepzelca’s current regulatory status at risk, raising uncertainty around a key oncology asset. Jazz Pharmaceuticals lung cancer drug fails main trial goal
• Negative Sentiment: Industry coverage from multiple outlets reinforced the setback, suggesting investor concern may persist until Jazz clarifies next steps for Zepzelca. Jazz Pharma announces late-stage trial setback for lung cancer therapy
• Negative Sentiment: FiercePharma noted the latest twist in the Zepzelca saga, highlighting the importance of the drug to Jazz’s cancer franchise and the market’s negative reaction to the failure. In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
• Negative Sentiment: Separately, an SEC filing showed EVP Neena M. Patil sold 1,200 shares earlier this week, a small insider sale that may add to cautious sentiment. Jazz Pharmaceuticals PLC EVP Neena M. Patil sold shares
• Neutral Sentiment: Some recent commentary still frames Jazz as a value stock with a “moderate buy” analyst consensus, but this is being overshadowed by the trial disappointment. Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares of the company’s stock, valued at $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the transaction, the director owned 384,682 shares of the company’s stock, valued at $73,281,921. The trade was a 1.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 11,941 shares of company stock valued at $2,565,339. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $230.56 on Friday. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32. The stock has a market cap of $14.48 billion, a price-to-earnings ratio of -11,522.24, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32. The business has a fifty day moving average of $217.61 and a 200-day moving average of $188.84. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion during the quarter. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.